Skip to main content
. 2014 Dec 5;5(23):11847–11856. doi: 10.18632/oncotarget.2663

Figure 1. Characterization of DiFi isogenic cell lines.

Figure 1

(A) DiFi isogenic cell lines (DiFi, DiFi-Mock1, DiFi-HRG4, DiFi-HRG5, and DiFi-HRG6) were cultured overnight in medium containing 10% serum and then incubated for 24 h in serum-free medium, after which the cells were lysed and subjected to immunoblot analysis with antibodies to heregulin and to β-actin (loading control). (B) Culture supernatants from cells cultured as described in Materials and Methods were assayed for heregulin with an ELISA. Data are means ± SE from three independent experiments. *P < 0.05 (Student's t test) for comparison of each DiFi-HRG line with DiFi-Mock1 or DiFi cells. (C) Cells were treated with cetuximab at the indicated concentrations for 5 days, after which cell viability was assessed. Data are means ± SE from three independent experiments.